A place of intravenous immunoglobulins in current clinical practice: Privigen is a novel 10% immunoglobulin
Intravenous immunoglobulins (IVIGs) were initially designed to treat patients with primary immunodeficiencies (PID). Due to the multidirectional effect of IVIGs on the immune system, a range of nosological entities, in which these agents are successfully administered, is steadily expanding. As of no...
Salvato in:
| Autori principali: | , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Russo |
| Pubblicazione: |
"Consilium Medicum" Publishing house
2016-04-01
|
| Serie: | Терапевтический архив |
| Soggetti: | |
| Accesso online: | https://ter-arkhiv.ru/0040-3660/article/viewFile/31987/pdf |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|